RAIN

Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
RAIN
Market cap $37.4M

5.45 USD

+0.00

0.00%

At close Jan 10, 4:00 PM EST

After hours

5.11

-0.34

6.24%

1 day

0.00%

5 days

2.83%

1 month

7.92%

3 months

7.92%

6 months

7.92%

Year to date

7.92%

1 year

7.92%

5 years

7.92%

10 years

7.92%

About: Rain Enhancement Technologies Holdco Inc, formerly Rain Enhancement Technologies Inc operates to develop, manufacture and commercialize ionization rainfall generation technology. This weather modification technology seeks to provide with reliable access to water, and transform business, society and the planet.

–

Funds holding %

of 6,814 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for RAIN.

See Analyst Rankings

Financial journalist opinion

Pathos AI Completes Acquisition of Rain Oncology

CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”) for $1.16 per share in cash plus one contingent value right per share (each, a “CVR”), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions.

Pathos AI Completes Acquisition of Rain Oncology

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

MILWAUKEE , Dec. 14, 2023 /PRNewswire/ -- Ademi LLP is investigating Rain (NASDAQ: RAIN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pathos. Click here to learn how to join the https://www.ademilaw.com/case/rain-oncology-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share is fair to Rain shareholders. Halper Sadeh encourages Rain shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060.

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share.

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

See News Rankings

Charts implemented using Lightweight Charts™